Preferentially increased brain volume loss in regions with high amyloid load was recently reported for a phase 3 trial of the BACE inhibitor verubecestat in mild-to-moderate Alzheimer’s disease [187]. The gene discussed is BACE1; the disease is Alzheimer disease.